deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT03275597

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Comprehensive Stereotactic Body Radiotherapy (SBRT) to All Sites of Oligometastatic Non-small Cell Lung Cancer (NSCLC) Combined With Durvalumab (MEDI4736) and Tremelimumab Dual Immune Checkpoint Inhibition.

Sponsor: AstraZeneca

Conditions Non-small Cell Lung Cancer Non-small Cell Lung Cancer Stage IV
Interventions Durvalumab Stereotactic Body Radiotherapy Tremelimumab
Updated 17 times since 2017 Last updated: May 11, 2023 Started: Feb 20, 2018 Primary completion: Jul 1, 2020 Completion: Jul 1, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

slow accrual

Other terminated trials from AstraZeneca

See all terminations from AstraZeneca

Other Non-small Cell Lung Cancer trials with similar outcome

Browse all Non-small Cell Lung Cancer trials

Listed as NCT03275597, this PHASE1 trial focuses on Non-small Cell Lung Cancer and Non-small Cell Lung Cancer Stage IV and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 17 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Oct 2017 – ~Mar 2018 · 5 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~Dec 2019 · 8 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Dec 2020 · 6 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jun 2023 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  4. Sep 2022 — Jun 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 12 earlier versions

  1. Sep 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  3. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1

  4. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  5. Jun 2020 — Dec 2020 [monthly]

    Recruiting PHASE1

  6. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE1

  7. Dec 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  8. Apr 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  9. Oct 2018 — Apr 2019 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  11. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  12. Oct 2017 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • University of Wisconsin, Madison
Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations